Navigation Links
A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,,,Cell Lines


LipoTAXI reagent is effective with a wide variety of cells

Leslie S. Arrington
Genetic Applications LLC

LipoTAXI transfection reagent can be used for simple and reproducible delivery of foreign DNA into mammalian cells. In this study, we used varying amounts of LipoTAXI transfection reagent to optimize conditions for transfecting a reporter plasmid in three common cell lines. In addition, the efficacy of LipoTAXI reagent was compared to four other leading transfection reagents. In these studies, LipoTAXI reagent outperformed other transfection reagents and was less toxic to cells.

Researchers can improve the efficiency of introducing foreign DNA into different mammalian cell lines by optimizing transfection reagents. Lipid-mediated transfection reagents surpass other types of transfection reagents because they are easy to use, gentle to cells and provide consistent reproducible results.1,2 However, among cell types, lipid-mediated transfection reagents can differ in transfection efficiency and proper dosage. Therefore, the first step to achieving high transfection efficiencies is to optimize the combination of lipid and DNA for each cell line.3 In this study, we examine the transfection efficiency of optimized LipoTAXI transfection reagent in A549, COS-7 and NIH 3T3 cell lines and compare this reagent to four other popular transfection products.

Optimization

For the initial optimization step, the signal strength of a reporter gene is measured as the amount of lipid is varied. The reporter plasmid (1.0 g) encoding the b-galactosidase gene was transfected into COS-7 cells with volumes of LipoTAXI transfection reagent that ranged between 6 and 15 l. The data demonstrate (Figure 1) that the highest transfection efficiency, as measured by b-galactosidase activity, occurred using 9 l of LipoTAXI reagent. This approach typically indicates the best amount of a transfection reagent for a particular cell line. Since high-level expression of a gene of interest may lead to unacceptably high cytotoxicity, total protein should be compared in cell lysates to select the optimal volume of LipoTAXI transfection reagent for the cell line studied.3

Figure 1

Comparison of Transfection Reagents

Using the results of the optimization experiment, we compared the efficacy of LipoTAXI transfection reagent to four other transfection reagents. Three of the reagents were cationic lipids; the fourth reagent was a branched polycationic polymer. All transfections included 1.0 g of reporter plasmid DNA. As determined for each cell line (Figure 1), the optimal amount of LipoTAXI transfection reagent was used. The other reagents were used at the volume recommended by the manufacturer. To ensure a fair comparison study, we also used the other reagents at slightly higher and lower amounts than recommended.

Figure 2

Analysis

The optimal amount of LipoTAXI transfection reagent varied considerably between cell lines. In general, the amount of transfection reagent that can be used is limited by cytotoxic effects of either the lipid or the expressed plasmid protein. The greater the amount of lipid tolerated by the cell line, the more transfection is achieved. To maximize the amount of lipid, we compared the concentration of cell proteins after transfections (data not shown). The A549 cell line seemed extremely tolerant to LipoTAXI transfection reagent as determined by the measurement of the total protein for the various volumes used. Even for 20 l of LipoTAXI transfection reagent, the concentration of cell protein was constant. For the other transfection agents, toxicity to cells increased as their amounts increased. Similar results were found when COS-7 and NIH 3T3 cell lines were transfected using 12 and 18 l of LipoTAXI transfection reagent, respectively. As shown in Figure 2, for the three volumes used, the other reagents demonstrated lower transfection efficiencies in all three cell lines.

Conclusions

These transfection studies first optimize LipoTAXI transfection reagent and then compare its efficacy to four other popularly used transfection reagents. Our comparison shows the superior efficiency and low toxicity of LipoTAXI reagent, features that make it the best transfection reagent for transfections in A549, COS-7 and NIH 3T3 cells.

REFERENCES
  1. Ausubel, F.M., et al. (1994) In Current Protocols in Molecular Biology. Wiley & Sons, New York.

  2. Jordan, M., Schallhorn, A., and Wurn, F.M. (1996) Nucleic Acids Res. 24: 596-601.

  3. Pingerelli, P., Petre, M., and Karmiol, S. (1997) Strategies 10: 8-9.

  4. Eustice, D.C., et al. (1991) Biotechniques 11: 739-743.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
2. Performance Comparisons of Commercial RT-PCR Systems
3. Comparison of Growth Techniques and Media for the Purpose of Plasmid Isolation from E. coli Using the Eppendorf Perfectprep Plasmid Mini Kit
4. TripleMaster PCR System: Direct Comparison with Competitors
5. Quantitative Measurement of Cell Proliferation Using the BrdU ELISA: A Comparison Between Colorimetric and Chemiluminescent Detection
6. Comparison of different protein quantitation methods
7. Comparison of Different Methods of mRNA Quantitation
8. Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A
9. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
10. Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A
11. Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain ... for adults at home or in healthcare facilities during periods of rest. A ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , ... Compass Research . GGI's mission is to advance global health and highlight the ... need in honor of each clinical trial volunteer. The vision of GGI is to ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members ... named Fellows of the Society this year, the Fellows Committee has announced. The ... of optics, photonics, and imaging as well as their service to the Society ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
Breaking Biology News(10 mins):